| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H18Cl2N2O3 |
| Molecular Weight | 381.253 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC2CCCC2)C=C(C=C1)C(=O)NC3=C(Cl)C=NC=C3Cl
InChI
InChIKey=RRRUXBQSQLKHEL-UHFFFAOYSA-N
InChI=1S/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23)
| Molecular Formula | C18H18Cl2N2O3 |
| Molecular Weight | 381.253 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Piclamilast (RP 73401), is a selective PDE4 inhibitor. It is comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as asthma, dermatitis, rheumatoid arthritis. Emesis is the most commonly cited side effect of piclamilast.
Originator
Approval Year
Sample Use Guides
1, 3 and 10 mg/kg were orally administered once daily
Route of Administration:
Oral
RP 73401 (IC50: 6.9 +/- 3.3 nM, n = 5) was 71 fold more potent than (+/-)-rolipram (IC50: 490 +/- 260 nM, n = 4) in inhibiting LPS-induced TNF alpha release from monocytes. RP 73401 (IC50: 2 nM) was 180 fold more potent than rolipram (IC50: 360 nM) in suppressing LPS (10 ng ml-1)-induced TNF alpha mRNA.
|
|
TARGET -> INHIBITOR |
42 NANOMOLAR (average) |
Showing 1 to 1 of 1 entries
